Establishes CAIRE Diagnostics Inc. business unit to broaden product portfolio
Ball Ground, GA (June 3, 2020) – CAIRE® Inc., a leader in respiratory solutions for the global health care community, announced the acquisition of Spirosure®, Inc. Spirosure is a California-based developer and manufacturer of an innovative technology for measuring Fractional Exhaled Nitric Oxide (FeNO), a key indicator of allergic inflammation in asthmatic patients.
It is estimated that asthma affects more than 300 million individuals worldwide and recent Global Initiative for Asthma (GINA) guidelines recommend FeNO measurement as an assessment tool in the management of asthma patients. FeNO is directly associated with infiltration of eosinophils in the airways and is elevated in individuals with allergic asthma. FeNO can be used to diagnose asthma, to detect nonadherence to inhaled corticosteroids (ICS), to be an early sign of worsening asthmatic inflammation and to manage difficult-to-control asthma because an elevated FeNO level can be predictive of a good response to ICS.
Japan-based NGK SPARK PLUG CO., LTD. acquired CAIRE in December 2018 to establish a global foothold in the respiratory therapy business and had previously invested in Spirosure as the latter company’s technology was in development. Spirosure will operate as a division of CAIRE to be known as CAIRE Diagnostics Inc., further expanding CAIRE’s portfolio into the diagnostic segment of respiratory care.
“We are very pleased to have found an excellent strategic buyer in CAIRE through one of our key investors,” said Solomon Ssenyange, PhD, CEO and Chairman of Spirosure. “CAIRE shares our commitment to technological leadership and, with its large international organization, is well-positioned to realize the full potential of our proprietary technology both commercially and with regard to our development pipeline. We look forward to an exciting future as part of CAIRE.”
Spirosure recently launched its first product to market, the Fenom Pro®, a reliable and convenient to use device that accurately measures FeNO at parts-per-billion levels using a proprietary sensor technology. The product is intended to be used in the clinic setting and is currently available in the United States, the EU and India.
“We are pleased to add Spirosure’s technology to our market-leading oxygen solution portfolio. FeNO is quickly becoming recognized by the clinical community as an important diagnostic and management tool for clinicians who treat asthma patients,” said Earl Lawson, President and CEO. “The acquisition of Spirosure further diversifies our portfolio and provides access to the 5 billion dollar respiratory diagnostic sector, a market segment where we anticipate rapid growth and adoption.”
About CAIRE Inc.
CAIRE Inc., headquartered in Ball Ground, GA, USA, has been a leading global manufacturer of oxygen supply equipment for more than 50 years. CAIRE’s portfolio, marketed under the AirSep®, CAIRE®, HELiOS™ and SeQual® brands, includes portable and stationary oxygen therapy devices and turnkey on-site generation commercial solutions. These products support home care, hospice, long-term care, hospitals, military, and key industrial applications. www.caireinc.com
About NGK SPARK PLUG CO., LTD.
NGK SPARK PLUG CO., LTD., headquartered in Nagoya, Japan, is a comprehensive ceramics processing manufacturer. The company is the world market leader in spark plugs and automotive sensors for internal combustion engines, and also offers a broad lineup of semiconductor packages, cutting tools, bioceramics and industrial ceramics. With more than 15,000 employees, our global network of sales and manufacturing organizations supports a sustainable society by developing products related to the environment, energy, next generation vehicles and the medical field. The company is committed to meeting the challenge of producing best-in-class, market-leading products in all fields.